[go: up one dir, main page]

AR041250A1 - Derivados de sulfonamida como inhibidores de enzimas convertidoras de tnf-alfa - Google Patents

Derivados de sulfonamida como inhibidores de enzimas convertidoras de tnf-alfa

Info

Publication number
AR041250A1
AR041250A1 ARP030103317A ARP030103317A AR041250A1 AR 041250 A1 AR041250 A1 AR 041250A1 AR P030103317 A ARP030103317 A AR P030103317A AR P030103317 A ARP030103317 A AR P030103317A AR 041250 A1 AR041250 A1 AR 041250A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
halo
cycloalkyl
group
Prior art date
Application number
ARP030103317A
Other languages
English (en)
Inventor
Howard Tucker
Jeremy Nicholas Burrows
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR041250A1 publication Critical patent/AR041250A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Reivindicación 1: Un compuesto caracterizado porque responde a la fórmula (1) o una sal aceptable para uso farmacéutico del mismo, donde: Y1 y Y2 son ambos O; z es NR8, O o S; n es 0 ó 1; W es NR1, CR1R2 o un enlace; V es NR15SO2; t es 0 ó 1; B esun grupo seleccionado entre arilo, heteroarilo y heterociclilo donde cada grupo está opcionalmente sustituido con uno o más grupo seleccionados en forma independiente entre nitro, trifluorometilo, trifluorometoxi, halo, ciano, alquilo C1-4(sustituido opcionalmente con halo o R9 o alcoxi C1-4 o uno o más halo), alquenilo C2-4 (sustituido opcionalmente con halo o R9), alquinilo C2-4 (sustituido opcionalmente con halo o R9), cicloalquilo C3-6 (sustituido opcionalmente con R9 o uno o máshalo), cicloalquenilo C5-6 (sustituido opcionalmente con halo o R9), arilo (sustituido opcionalmente con halo o alquilo C1-4), heteroarilo (sustituido opcionalmente con halo o alquilo C1-4), heterociclilo (sustituido opcionalmente con alquilo C1-4),-SR11, -SOR11, -SO2R11, -SO2NR9R10, -NR9SO2R11, -NHCONR9R10, -OR9, -NR9R10, -CONR9R10 y -NR9COR10; o B es alquenilo C2-4 o alquinilo C2-4, donde cada uno está opcionalmente sustituido con un grupo seleccionado entre alquilo C1-4, cicloalquilo C3-6,arilo, heteroarilo y heterociclilo, donde este grupo está opcionalmente sustituido con uno o más halo, nitro, ciano, trifluorometilo, trifluorometoxi, -CONHR9, -CONR9R10, -SO2R11, -SO2NR9R10, -NR9SO2R11, alquilo C1-4 o alcoxi C1-4; R1 y R2 son enforma independiente hidrógeno o un grupo seleccionado entre alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6 y cicloalquenilo C5-6 donde el grupo puede estar opcionalmente sustituido con halo, ciano, nitro, hidroxi o alcoxi C1-4; R3,R4,. R5 y R6 son en forma independiente hidrógeno o un grupo seleccionado entre alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, cicloalquenilo C5-6, arilo, heteroarilo y heterociclilo donde el grupo está opcionalmente sustituido conuno o más sustituyentes seleccionados en forma independiente entre halo, nitro, ciano, trifluorometilo, trifluorometiloxi, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, cicloalquilo C3-6 (sustituido opcionalmente con uno o más R17), arilo(sustituido opcionalmente con uno o más R17), heteroarilo (sustituido opcionalmente con uno o más R17), heterociclilo, -OR18, -SR19, -SOR19, -SO2R19, -COR19, -CO2R18, -CONR18R20, -NR16COR18, -SO2NR18R20 y -NR16SO2R19; o R1 y R3 junto con el átomo denitrógeno o carbono y el átomo de carbono a los cuales están unidos respectivamente forman un anillo saturado de 3 a 7 miembros que contiene opcionalmente 1 ó 2 grupos heteroátomos seleccionados entre NH, O, S, SO y SO2 donde el anillo estáopcionalmente sustituido sobre carbono con alquilo C1-4, alcoxi C1-3 o flúor y/o sobre nitrógeno con -COalquilo C1-3, -SO2alquilo C1-3 o alquilo C1-4; o R3 y R4 juntos forman un anillo saturado de 3 a 7 miembros que contiene opcionalmente un grupoheteroatómico seleccionado entre NH, O, S, SO y SO2 donde el anillo está opcionalmente sustituido sobre carbono con alquilo C1-4, alcoxi C1-3 o flúor y/o sobre nitrógeno con alquilo -COalquilo C1-3, -SO2alquilo C1-3 y/o alquilo C1-4; o R3 y R5 juntocon los átomos de carbono a los cuales están unidos forman un anillo saturado de 3 a 7 miembros que contiene opcionalmente un grupo heteroatómico seleccionado entre NH, O, S, SO y SO2 donde el anillo está opcionalmente sustituido sobre carbono conalquilo C1-4, alcoxi C1-3 o flúor y/o sobre nitrógeno con -COalquilo C1-3, -SO2alquilo C1-3 o alquilo C1-4; o R5 y R6 juntos forman un anillo saturado de 3 a 7 miembros que contiene opcionalmente un grupo heteroatómico seleccionado entre NH, O, S,SO y SO2 donde el anillo está opcionalmente sustituido sobre carbono con alquilo C1-4, alcoxi C1-3 o flúor y/o sobre nitrógeno con -COalquilo C1-3, -SO2alquilo C1-3 o alquilo C1-4; R7 es hidrógeno o un grupo seleccionado entre alquilo C1-6,alquenilo C2-6, alquinilo C2-6, heteroalquilo, cicloalquilo C3-7, arilo heteroarilo y heterociclilo donde el grupo está opcionalmente sustituido con halo, alquilo C1-4, alcoxi C1-4, cicloalquilo C3-7, heterociclilo, arilo, heteroarilo oheteroalquilo; y donde el grupo del cual puede seleccionarse R7 está opcionalmente sustituido sobre el grupo y/o sobre su sustituyente opcional con uno o más sustituyentes seleccionados en forma independiente entre halo, ciano, alquilo C1-4, nitro,haloalquilo C1-4, heteroalquilo, arilo, heteroarilo, hidroxialquilo C1-4, cicloalquilo C3-7, heterociclilo, alcoxi(C1-4)alquilo(C1-4), haloalcoxi(C1-4)alquilo(C1-4), -COalquilo C1-4, -OR21, -CO2R21, -SR21, -SOR21, -SO2R21, -NR21COR22, -CONR21R22 y-NHCONR21R22; o R3 y R7 junto con los átomos de carbono a los cuales cada uno está unido y (CR5R6)n forman un anillo saturado de 5 a 7 miembros que contiene opcionalmente un grupo heteroatómico seleccionado entre NH, O, S, SO y SO2 donde el anilloestá opcionalmente sustituido sobre carbono con alquilo C1-4, alcoxi C1-3 o flúor y/o sobre nitrógeno con -COalquilo C1-3, -SO2alquilo C1-3 o alquilo C1-4; R8 se selecciona entre nitrógeno o metilo; R9 y R10 son en forma independiente hidrógeno,alquilo C1-6 o cicloalquilo C3-6; o R9 y R10 junto con el nitrógeno al cual están unidos forman un anillo heterocíclico de 4 a 7 miembros; R11 es alquilo C1-6 o cicloalquilo C3-6; R12 y R13 se seleccionan en forma independiente entre hidrógeno,alquilo C1-6 y cicloalquilo C3-6; R15 es hidrógeno o alquilo C1-3; R16 es hidrógeno o alquilo C1-6; R17 se selecciona entre halo, alquilo C1-6, cicloalquilo C3-6 y alcoxi C1-6; R18 es hidrógeno o un grupo seleccionado entre alquilo C1-6,cicloalquilo C3-6, cicloalquenilo C5-6, heterociclilo saturado, arilo, heteroarilo, arilalquilo C1-4 y heteroarilalquilo C1-4 donde el grupo está opcionalmente sustituido con uno o más halo; R19 y R25 son en forma independiente un grupo seleccionadoentre alquilo C1-6, cicloalquilo C3-6, cicloalquenilo C5-6, heterociclilo saturado, arilo, heteroarilo, arilalquilo C1-4, y heteroarilalquilo C1-4 donde el grupo está opcionalmente sustituido con uno o más halo; R20 es hidrógeno, alquilo C1-6 ocicloalquilo C3-6; o R18 y R20 junto con el átomo de nitrógeno al cual están unidos forman un anillo heterociclilo de 4 a 7 miembros; R21 y R22 son en forma independiente hidrógeno, alquilo C1-4, haloalquilo C1-4, arilo y arilalquilo C1-4; con lacondición de que un compuesto de la fórmula (1) no sea 1-(4-metil-2,5-dioxoimidazolidin-4-il)-N-[4-(4-clorofenoxi)fenil]metansulfonamida.
ARP030103317A 2002-09-13 2003-09-12 Derivados de sulfonamida como inhibidores de enzimas convertidoras de tnf-alfa AR041250A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0221246.2A GB0221246D0 (en) 2002-09-13 2002-09-13 Compounds

Publications (1)

Publication Number Publication Date
AR041250A1 true AR041250A1 (es) 2005-05-11

Family

ID=9943999

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP030103319A AR043049A1 (es) 2002-09-13 2003-09-12 Derivados de hidantoina, proceso de preparacion del mismo y composicion farmaceutica
ARP030103317A AR041250A1 (es) 2002-09-13 2003-09-12 Derivados de sulfonamida como inhibidores de enzimas convertidoras de tnf-alfa

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP030103319A AR043049A1 (es) 2002-09-13 2003-09-12 Derivados de hidantoina, proceso de preparacion del mismo y composicion farmaceutica

Country Status (19)

Country Link
US (2) US20050256176A1 (es)
EP (2) EP1551826A1 (es)
JP (2) JP2006507248A (es)
KR (1) KR20050042499A (es)
CN (1) CN1681804A (es)
AR (2) AR043049A1 (es)
AU (2) AU2003263347A1 (es)
BR (1) BR0314275A (es)
CA (1) CA2497571A1 (es)
GB (1) GB0221246D0 (es)
IS (1) IS7792A (es)
MX (1) MXPA05002602A (es)
NO (1) NO20051788L (es)
PL (1) PL375877A1 (es)
RU (1) RU2005106353A (es)
TW (2) TW200409769A (es)
UY (1) UY27972A1 (es)
WO (2) WO2004024721A1 (es)
ZA (1) ZA200501677B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0103710D0 (sv) 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
US7132432B2 (en) * 2003-06-05 2006-11-07 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)
WO2005000309A2 (en) * 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
GB0405101D0 (en) * 2004-03-06 2004-04-07 Astrazeneca Ab Compounds
CN1956952B (zh) * 2004-06-02 2013-12-11 伊莱利利公司 组胺h3受体药剂、制备和治疗学用途
SE0401763D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Compounds
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0401762D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
US7488745B2 (en) 2004-07-16 2009-02-10 Schering Corporation Compounds for the treatment of inflammatory disorders
CA2573764A1 (en) * 2004-07-16 2006-02-23 Schering Corporation Hydantoin derivatives for the treatment of inflammatory disorders
US7504424B2 (en) 2004-07-16 2009-03-17 Schering Corporation Compounds for the treatment of inflammatory disorders
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
AR059037A1 (es) * 2006-01-17 2008-03-12 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
US7612212B2 (en) 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
TW200740769A (en) * 2006-03-16 2007-11-01 Astrazeneca Ab Novel process
US20100226922A1 (en) * 2006-06-08 2010-09-09 Dorothea Maetzel Specific protease inhibitors and their use in cancer therapy
JP2008007507A (ja) * 2006-06-28 2008-01-17 Teva Pharmaceutical Industries Ltd 結晶形アトルバスタチン
TW200831488A (en) 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
AU2009271302A1 (en) * 2008-06-24 2010-01-21 Valeant Pharmaceuticals International Benzyloxy anilide derivatives useful as potassium channel modulators
AR073307A1 (es) 2008-09-24 2010-10-28 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
AR073741A1 (es) 2008-09-24 2010-12-01 Schering Corp Derivados heterociclicos de hidantoina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias, tales como psoriasis o artritis
WO2010054279A1 (en) 2008-11-10 2010-05-14 Schering Corporation Compounds for the treatment of inflammatory disorders
WO2010054278A2 (en) 2008-11-10 2010-05-14 Schering Corporation Compounds for the treatment of inflammatory disorders
WO2013085016A1 (ja) * 2011-12-09 2013-06-13 科研製薬株式会社 ピリドン誘導体およびそれを含有する医薬
JP6450323B2 (ja) 2013-01-07 2019-01-09 ユニバーシティ オブ サザン カリフォルニア デオキシウリジントリホスファターゼ阻害剤
TWI636782B (zh) 2013-06-07 2018-10-01 科研製藥股份有限公司 （＋）－５－（３,４－二氟苯基）－５－［（３－甲基－２－氧代吡啶－１（２ｈ）－基）甲基］咪唑啶－２,４－二酮及含有此之醫藥
US10544105B2 (en) 2015-07-08 2020-01-28 Cv6 Therapeutics (Ni) Limited Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage
US10577321B2 (en) 2015-07-08 2020-03-03 University Of Southern California Deoxyuridine triphosphatase inhibitors
PT3319939T (pt) 2015-07-08 2025-03-05 Cv6 Therapeutics Ni Ltd Inibidores de desoxiuridina-trifosfatase contendo hidantoína
US10570100B2 (en) 2015-07-08 2020-02-25 University Of Southern California Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage
WO2018098206A1 (en) * 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
WO2018098208A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Nitrogen ring linked deoxyuridine triphosphatase inhibitors
US11168059B2 (en) 2016-11-23 2021-11-09 Cv6 Therapeutics (Ni) Limited Amino sulfonyl compounds
US11174271B2 (en) 2016-11-23 2021-11-16 Cv6 Therapeutics (Ni) Limited 6-membered uracil isosteres
US11014924B2 (en) 2016-11-23 2021-05-25 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
US11247984B2 (en) 2017-01-05 2022-02-15 Cv6 Therapeutics (Ni) Limited Uracil containing compounds
EP4058437B9 (en) * 2019-11-14 2025-01-15 Foresee Pharmaceuticals USA, Inc. Matrix metalloproteinase (mmp) inhibitors and methods of use thereof
EP3822268A1 (en) 2019-11-15 2021-05-19 Bayer Aktiengesellschaft Substituted hydantoinamides as adamts7 antagonists
EP3822265A1 (en) 2019-11-15 2021-05-19 Bayer AG Substituted hydantoinamides as adamts7 antagonists

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2745875A (en) * 1953-06-30 1956-05-15 Hoechst Ag Preparation of nu-acylamino-phenylpropane diols
US3452040A (en) * 1966-01-05 1969-06-24 American Home Prod 5,5-disubstituted hydantoins
US3529019A (en) * 1968-04-23 1970-09-15 Colgate Palmolive Co Alkylaryloxy alanines
US3849574A (en) * 1971-05-24 1974-11-19 Colgate Palmolive Co Alpha-substituted-beta-arylthioalkyl amino-acids,for increasing heart rate
US4315031A (en) * 1977-09-01 1982-02-09 Science Union Et Cie Thiosubstituted amino acids
GB1601310A (en) * 1978-05-23 1981-10-28 Lilly Industries Ltd Aryl hydantoins
JPS61212292A (ja) * 1985-03-19 1986-09-20 Mitsui Toatsu Chem Inc Ｄ−α−アミノ酸の製造方法
PH31245A (en) * 1991-10-30 1998-06-18 Janssen Pharmaceutica Nv 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
US5308853A (en) * 1991-12-20 1994-05-03 Warner-Lambert Company Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US6166041A (en) * 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
PL326710A1 (en) * 1995-11-22 1998-10-26 Darwin Discovery Ltd Mercaptoalkylpeptidic compounds having an imidazolic substituent and their application as inhibitors of intercellular substance metaloproteinases and/or of tumor necrosis factor (tnf)
GB9616643D0 (en) * 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
US5919790A (en) * 1996-10-11 1999-07-06 Warner-Lambert Company Hydroxamate inhibitors of interleukin-1β converting enzyme
ATE212619T1 (de) * 1996-10-22 2002-02-15 Upjohn Co Alpha-amino sulfonyl hydroxamsäure als matrix metalloproteinase inhibitoren
IL132170A0 (en) * 1997-05-06 2001-03-19 Novo Nordisk As Novel heterocyclic compounds
DK0877019T3 (da) * 1997-05-09 2002-04-08 Hoechst Ag Substituerede diaminocarboxylsyrer
CA2318145C (en) * 1998-02-04 2009-10-27 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
US6329418B1 (en) * 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
CA2330095A1 (en) * 1998-05-14 1999-11-18 Dupont Pharmaceuticals Company Substituted aryl hydroxamic acids as metalloproteinase inhibitors
AU4692399A (en) * 1998-06-17 2000-01-05 Du Pont Pharmaceuticals Company Cyclic hydroxamic acids as metalloproteinase inhibitors
US6339101B1 (en) * 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
ES2213985T3 (es) * 1998-11-05 2004-09-01 Pfizer Products Inc. Derivados de hidroxiamida de acido 5-oxo-pirrolidin-2-carboxilico.
US6340691B1 (en) * 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
EE200200065A (et) * 1999-08-12 2003-04-15 Pharmacia Italia S.P.A. 3-aminopürasooli derivaadid, nende valmistamine ja kasutamine vähivastaste toimeainetena ning neid sisaldav farmatseutiline kompositsioon
US6525202B2 (en) * 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US20020091107A1 (en) * 2000-09-08 2002-07-11 Madar David J. Oxazolidinone antibacterial agents
DE10047073C1 (de) * 2000-09-22 2002-01-24 Dbt Gmbh Hydraulisch schaltbares Wegeventil
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
EE200300439A (et) * 2001-03-15 2003-12-15 Astrazeneca Ab Metalloproteinaasi inhibiitorid
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
WO2002096426A1 (en) * 2001-05-25 2002-12-05 Bristol-Myers Squibb Company Hydantion derivatives as inhibitors of matrix metalloproteinases
SE0103710D0 (sv) * 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
SE0202539D0 (sv) * 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
TWI220073B (en) * 2003-07-24 2004-08-01 Au Optronics Corp Method for manufacturing polysilicon film

Also Published As

Publication number Publication date
KR20050042499A (ko) 2005-05-09
EP1551826A1 (en) 2005-07-13
RU2005106353A (ru) 2005-10-10
AR043049A1 (es) 2005-07-13
CN1681804A (zh) 2005-10-12
JP2006503829A (ja) 2006-02-02
WO2004024715A1 (en) 2004-03-25
CA2497571A1 (en) 2004-03-25
MXPA05002602A (es) 2005-05-05
US20050256176A1 (en) 2005-11-17
TW200409769A (en) 2004-06-16
ZA200501677B (en) 2005-09-12
AU2003263347A1 (en) 2004-04-30
WO2004024721A1 (en) 2004-03-25
GB0221246D0 (en) 2002-10-23
BR0314275A (pt) 2005-08-09
EP1539740A1 (en) 2005-06-15
NO20051788L (no) 2005-06-13
AU2003263345A1 (en) 2004-04-30
JP2006507248A (ja) 2006-03-02
UY27972A1 (es) 2004-04-30
TW200406398A (en) 2004-05-01
IS7792A (is) 2005-04-11
PL375877A1 (en) 2005-12-12
US20060063818A1 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
AR041250A1 (es) Derivados de sulfonamida como inhibidores de enzimas convertidoras de tnf-alfa
AR069412A1 (es) Derivados de pirimidina, proceso para prepararlos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades virales, bacterianas y alergicas, entre otras.
AR064130A1 (es) Derivados de tiazoles y piridinas como antibacterianos. composiciones farmaceuticas.
AR046779A1 (es) Derivados de pirazol, metodos para su preparacion y usos de los mismos en la fabricacion de composiciones farmaceuticas y medicamentos que los contienen con actividad inhibitoria de trk para el tratamiento o profilaxis del cancer.
AR066492A1 (es) Derivados de imidazoquinolina, proceso para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de enfermedades virales, bacterianas, alergicas y distintos tipos de canceres.
ES2570127T3 (es) Compuestos y composiciones como inhibidores de la proteína quinasa
AR070636A1 (es) Derivados de piridina, composicion farmaceutica y uso terapeutico
AR064345A1 (es) Derivados de 8-oxoadenina
CO6251248A2 (es) Compuestos de tiazolopiridina como moduladores de sirtuina
EA200970461A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
AR044152A1 (es) Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
AR062258A1 (es) Compuestos heterociclicos condensados de tieno-pirrol, composiciones farmaceuticas que los contienen y usos para el tratamiento de infecciones por hcv
AR071370A1 (es) Derivados tiazolicos peptidicos utiles como inhibidores de vhc y composiciones farmaceuticas que los contienen.
AR046244A1 (es) Activadores de glucoquinasa heteroaromaticos de seis miembros 5- sustituidos
AR052458A1 (es) Amino-imidazolonas para la inhibicion de beta-secretasa
AR072047A1 (es) Compuestos heterociclicos utiles para inhibir la adn girasa
AR064208A1 (es) Derivados de piridin-3-il-quinazolinas como inhibidores de b-raf. procesos de obtencion y composiciones farmaceuticas.
AR051966A1 (es) Derivados de acido fenoxiacetico utiles para el tratamiento de enfermedades respiratorias
AR041196A1 (es) Derivados de piperidina, preparacion del compuesto y composicion farmaceutica que lo contiene
AR052330A1 (es) Derivados de adamantano que comprenden quinoleinas sustituidas
AR072045A1 (es) Derivados heterociclicos de urea y metodos para utilizarlos
AR076176A1 (es) Derivados de amida de pirazol (3,2-c) esteroides con actividad agonista del receptor de glucocorticoesteroides
AR063625A1 (es) COMPUESTOS HETEROCICLICOS eTILES COMO AGENTES ANTICANCEROSOS
AR047537A1 (es) Piridazinonaureas como antagonistas de integrinas
AR057855A1 (es) Derivados de pirazina y composicion farmaceutica

Legal Events

Date Code Title Description
FB Suspension of granting procedure